Search results for "portion"

showing 10 items of 902 documents

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017

<b><i>Background/Aim:</i></b> Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. <b><i>Methods:</i></b> Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. <b><i>Resu…

AdultMaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsYoung Adult03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSurvival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetabolic Syndromebusiness.industryProportional hazards modelPhenylurea CompoundsLiver NeoplasmsHazard ratioGastroenterologyGeneral MedicineMiddle AgedSorafenibPrognosismedicine.diseaseSurvival Analysisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisFemale030211 gastroenterology & hepatologyMetabolic syndromebusinessDyslipidemiamedicine.drugDigestive Diseases
researchProduct

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers

2019

Background The identification of appropriate biomarkers is essential to support important clinical decisions in patients with prostate cancer. The aim of our study was a systematic bioinformatical analysis of the mRNA expression of all genes available for the prostate adenocarcinoma cohort of The Cancer Genome Atlas (TCGA), regarding their potential prognostic and diagnostic role. Methods The study cohort comprises 499 patients (TCGA prostate cancer cohort). mRNA expression data were available for approx. 20,000 genes. The bioinformatical statistical pipeline addressed gene expression differences in tumor vs. benign prostate tissue (including gene set enrichment analysis, GSEA) in samples f…

AdultMaleOncologyBiochemical recurrencemedicine.medical_specialtyBiomedical ResearchMultivariate analysisBioinformaticsUrology030232 urology & nephrologyAdenocarcinomalcsh:RC870-923PrognosticCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansDiagnosticEpigeneticsAgedProstate cancerProportional hazards modelbusiness.industryHazard ratiomRNA expressionProstatic NeoplasmsGeneral MedicineMiddle Agedlcsh:Diseases of the genitourinary system. UrologyPrognosismedicine.diseaseGene Expression Regulation NeoplasticReproductive Medicine030220 oncology & carcinogenesisCohortBiomarker (medicine)businessBiomarkersResearch ArticleBMC Urology
researchProduct

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity

2006

This study tested the hypothesis that GLUT-1 is a marker of radioresistance in oral squamous cell carcinomas (OSCC). A GLUT-1 labeling index (LI) was determined by immunohistochemistry in 40 pretreatment OSCC biopsies. Radiation responses were categorized by histopathology of the resection specimens. Associations between the LI and radiation response, Kaplan-Meier survival estimates and Cox regression analysis for the variables GLUT-1, T-stage, N-stage and chemotherapy were examined. The median LI was 64.2% (range 14-100%). Tumors with65% of GLUT-1+cells were more resistant to radiation (p=0.023). Overall survival was higher (p=0.044) for subjects with low LI (median value) than those with …

AdultMaleOncologyendocrine systemCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentAntineoplastic AgentsRadiation ToleranceImmunoenzyme TechniquesRadioresistanceInternal medicineBiomarkers TumorHumansMedicineAgedRetrospective StudiesGlucose Transporter Type 1Chemotherapybusiness.industryProportional hazards modelHead and neck cancerMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisNeoplasm ProteinsRadiation therapystomatognathic diseasesTreatment OutcomeOncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmsHistopathologyOral Surgerybusinesshormones hormone substitutes and hormone antagonistsOral Oncology
researchProduct

Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009

2013

The aim of this study was to analyze clinical presentation, course of disease, and management of patients with hepatocellular carcinoma (HCC) in a German referral center between 1998 and 2009.HCC is a rare tumor in Germany, but its incidence has increased over the last 30 years. New therapies such as chemoembolization with drug-eluting beads, selective internal radiotherapy, and sorafenib were introduced recently; however, the impact on clinical management and overall survival (OS) is unclear.In this retrospective analysis, 1066 patients with HCC, separated into two 6-year periods (n=385; 1998 to 2003 and n=681; 2004 to 2009) were evaluated.The number of patients presenting each year (64 vs…

AdultMaleOncologymedicine.medical_specialtyCarcinoma HepatocellularTime FactorsAdolescentKaplan-Meier EstimateMedical OncologyRisk AssessmentArticleTertiary Care CentersGermanYoung AdultRisk FactorsGermanyInternal medicineEpidemiologymedicineCarcinomaHumansRegistriesYoung adultAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overbusiness.industryProportional hazards modelIncidence (epidemiology)Liver NeoplasmsAge FactorsGastroenterologyRetrospective cohort studyMiddle Agedmedicine.diseasedigestive system diseaseslanguage.human_languageTreatment OutcomeHepatocellular carcinomalanguageFemalebusinessJournal of Clinical Gastroenterology
researchProduct

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

2005

Summary Background Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods We analysed data for 1265 patients who received chemotherapy (vinorelbine, gemcitabine, gemcitabine and vinorelbine, cisplatin and vinorelbine, or cisplatin and gemcitabine) within three randomised trials. Primary landmark analyses were restricted to 436 patients who received all six planned chemotherapy cycles and who were alive 180 days after randomisation. Neutropenia was categorised on the basis of worst WHO g…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentAntineoplastic AgentsNeutropenia.VinorelbineSeverity of Illness IndexCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansLung cancerSurvival rateAgedProportional Hazards ModelsRandomized Controlled Trials as TopicAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryStandard treatmentHazard ratioMiddle Agedrandomized clinical trialmedicine.diseaseGemcitabineSurgerySurvival Ratelandmark analysisnon-small-cell lung cancerItalyOncologychemotherapy-induced neutropeniaFemaleDrug MonitoringbusinessBiomarkersmedicine.drug
researchProduct

High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer

2020

Abstract Background The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet. Objectives The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC. Methods In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier…

AdultMaleOncologymedicine.medical_specialtyReceptor complexUrologymedicine.medical_treatment030232 urology & nephrologyCystectomyCohort StudiesCystectomyInterleukin 2203 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineHumansNeoplasm InvasivenessAgedAged 80 and overMuscle NeoplasmsBladder cancerProportional hazards modelbusiness.industryReceptors InterleukinMiddle AgedPrognosismedicine.diseaseSurvival RateUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisCohortT-stageFemalebusinessFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

Ophthalmic Outcomes of Congenital Toxoplasmosis Followed Until Adolescence

2014

BACKGROUND: Congenital toxoplasmosis (CT) can elicit severe damage to several organs, especially the eye, and may be manifested at birth or later. We assessed the long-term ocular prognosis in a cohort of congenitally infected children treated according to a standardized protocol and monitored for up to 22 years. METHODS: This prospective study included confirmed cases of CT, which were identified by obligatory antenatal screening at the Lyon (France) reference center between 1987 and 2008. Data obtained through ocular examinations were recorded on a standardized form and confirmed by an independent external committee. Risk factors for retinochoroiditis were identified by using a multivari…

AdultMalePediatricsmedicine.medical_specialtyAdolescentEye DiseasesToxoplasmosis CongenitalCohort StudiesLesionYoung AdultPregnancyHumansMedicineProspective StudiesChildProspective cohort studybusiness.industryProportional hazards modelChorioretinitisInfantmedicine.diseaseCongenital toxoplasmosisMaternal infectionTreatment OutcomeChild PreschoolPregnancy Complications ParasiticPediatrics Perinatology and Child HealthCohortOcular lesionFemaleFrancemedicine.symptombusinessFollow-Up StudiesPediatrics
researchProduct

Second Malignancies Following Childhood Cancer Treatment in Germany From 1980 to 2014.

2018

BACKGROUND Because of improvements in cancer treatment, more than 80% of all children with cancer now survive at least five years from the time of diagnosis. As a result, late sequelae of cancer and its treatment have become more common, particularly second malignancies. We studied the current incidence of second malignancies among childhood cancer survivors in Germany. METHODS This study is based on the cohort of the German Childhood Cancer Registry (Deutsches Kinderkrebsregister, DKKR). Persons given the diagnosis of a first malignancy at any time in the years 1980-2014 who were no more than 14 years old at the time of diagnosis and survived at least six months thereafter were included in…

AdultMalePediatricsmedicine.medical_specialtyPopulationMalignancy03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsRisk FactorsGermanymedicineHumansCumulative incidence030212 general & internal medicineRegistrieseducationChildProportional Hazards Modelseducation.field_of_studyChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceHazard ratioCancerNeoplasms Second PrimaryGeneral MedicineMiddle Agedmedicine.diseaseAdult Survivors of Child Adverse Events030220 oncology & carcinogenesisCohortFemaleOriginal ArticlebusinessDeutsches Arzteblatt international
researchProduct

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients

2012

Three hundred and twenty-seven patients from two population-based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors for survival and leukaemia in a long-term survey. The relative survival (RS) was 72% and 46% at 10 and 20 years respectively, from the time of diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 10(9) /l and thrombo-embolism at diagnosis as independent risk factors. Patients with two or three of these factors had a 10 year RS of 26%, compared with 59% and 84% in patients with one and no risk factors, respectively. Age and leucocyte count are the main predicting factors for survival in polycy…

AdultMalePolycythaemiamedicine.medical_specialtyLeukocytosisPopulationComorbidityKaplan-Meier EstimateLeukocyte CountYoung AdultPolycythemia veraRisk FactorsCause of DeathNeoplasmshemic and lymphatic diseasesWhite blood cellInternal medicineEpidemiologymedicineHumansRisk factoreducationPolycythemia VeraAgedProportional Hazards ModelsAged 80 and overHeart FailureSwedeneducation.field_of_studyRelative survivalProportional hazards modelbusiness.industryThrombosisHematologyMiddle AgedPrognosismedicine.diseaseSurgeryLeukemia Myeloid Acutemedicine.anatomical_structureDisease ProgressionFemaleFrancebusinessFollow-Up StudiesBritish Journal of Haematology
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct